Noventure is a portfolio of clinically proven, consumer-facing healthcare brands trusted by healthcare professionals and patients in more than 50 countries. Our mission is to build trust for people all around the world by providing clinically-backed products that offer real relief without harm—so they can live healthier, freer lives without fear or doubt in their care. Our brands, including Tasectan, Utipro Plus, and Ulkox, are: • Backed by clinical trials • Included in treatment guidelines • CE-marked and MDR Class III compliant • Protected by patents We work with leading pharmaceutical partners worldwide to make our products the number one choice in their therapeutic class.
Looking for a particular Noventure employee's phone or email?
The Noventure annual revenue was $9 million in 2026.
Ignacio Mena is the Managing Director of Noventure.
17 people are employed at Noventure.
Noventure is based in Barcelona, Catalonia.
The NAICS codes for Noventure are [424, 42421, 42, 4242].
The SIC codes for Noventure are [51, 512].